Avalo Therapeutics Inc
NASDAQ:AVTX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/GP
Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.
Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.
Valuation Scenarios
If EV/GP returns to its 3-Year Average (1.6), the stock would be worth $0 (100% downside from current price).
| Scenario | EV/GP Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 4 693 | $13.67 |
0%
|
| 3-Year Average | 1.6 | $0 |
-100%
|
| 5-Year Average | 736.2 | $2.14 |
-84%
|
| Industry Average | 6.4 | $0.02 |
-100%
|
| Country Average | 6.5 | $0.02 |
-100%
|
Forward EV/GP
Today’s price vs future gross profit
Peer Comparison
| Market Cap | EV/GP | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Avalo Therapeutics Inc
NASDAQ:AVTX
|
357.9m USD | 4 693 | -3.2 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 0 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
373.6B USD | 9.7 | 87.8 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
186.6B USD | 7.2 | 22.9 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
162.4B USD | 7.5 | 19.2 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 769.8 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
108.6B USD | 9.7 | 27.3 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
74.7B USD | 4.2 | 16.5 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.3B EUR | 11.9 | 37.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 26 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
60B AUD | 6.4 | 29.6 |
Market Distribution
| Min | 0 |
| 30th Percentile | 4.2 |
| Median | 6.5 |
| 70th Percentile | 10.6 |
| Max | 1 764 211.7 |
Other Multiples
Avalo Therapeutics Inc
Glance View
Avalo Therapeutics, Inc. is a biopharmaceutical company. The company is headquartered in Rockville, Maryland and currently employs 42 full-time employees. The company went IPO on 2015-11-13. The firm discovers, develops, and commercializes therapeutics for patients with unmet clinical needs in immunology and rare genetic diseases. Its clinical-stage pipeline includes AVTX-002, AVTX-007, and AVTX-800 programs. AVTX-002 is an Anti-LIGHT monoclonal antibody for treatment of non-eosinophilic asthma, moderate to severe inflammatory bowel disease, and COVID-19 acute respiratory distress syndromes. AVTX-007 is a fully human monoclonal antibody for the treatment of Still’s Disease, including adult-onset Still’s disease (AOSD) and systemic juvenile jdiopathic Arthritis (SJIA). Its AVTX-800 programs include AVTX-801 and AVTX-803, AVTX-802, AVTX-008, and AVTX-006. VTX-801 and AVTX-803 are monosaccharide therapies for the treatment of congenital disorders of glycosylation (CDGs). AVTX-006 is a dual mTORc1/c2 small molecule inhibitor for the treatment of complex lymphatic malformations.
